In a phase I/II trial evaluating a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer, GM-CSF co-administration was associated with enhanced CD8+ T-cell responses targeting PAP and PSA, along with durable immune memory in long-term follow-up (Table 3) [37]. Here, CD8A is linked to prostate cancer.